Feasibility of 3T Dynamic Contrast-Enhanced Magnetic Resonance-Guided Biopsy in Localizing Local Recurrence of Prostate Cancer after External Beam Radiation Therapy

Investigative Radiology

Volumn 45, Issue 3, 2010, Pages 121-125

  Yakar, Derya ^a   Hambrock, Thomas ^a   Huisman, Henkjan ^a   Hulsbergen Van De Kaa, Christina A ^a   Van Lin, Emile ^a   Vergunst, Henk ^b   Hoeks, Caroline M A ^a   Van Oort, Inge M ^a   Witjes, J Alfred ^a   Barentsz, Jelle O ^a   Fütterer, Jurgen J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Biopsy; External beam radiation therapy; Functional magnetic resonance imaging; Local recurrence; Prostatic neoplasms

Indexed keywords

CIPROFLOXACIN; RECOMBINANT GLUCAGON; SCOPOLAMINE BUTYL BROMIDE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EXTERNAL BEAM RADIOTHERAPY; FEASIBILITY STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; THREE DIMENSIONAL IMAGING;

EID: 77249144015     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181c7bcda     Document Type: Article

References (28)

1. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973-1995, SEER Program. Bethesda, MD: National Cancer Institute; 1999.
2. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95:281-286.
3. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2005;48:546-551.
4. Horwitz EM, Vicini FA, Ziaja EL, et al; American Society of Therapeutic Radiology and Oncology. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys. 1998;41:267-272.
5. Nudell DM, Wefer AE, Hricak H, et al. Imaging for recurrent prostate cancer. Radiol Clin North Am. 2000;38:213-229.
6. Kestin LL, Vicini FA, Ziaja EL, et al. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer. 1999;86:1557-1566.
7. Pound CR, Brawer MK, Partin AW. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol. 2001;3:72-84.
8. Crook J, Robertson S, Collin G, et al. Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1993;27:31-37.
9. Chan TW, Kressel HY. Prostate and seminal vesicles after irradiation: MR appearance. J Magn Reson Imaging. 1991;1:503-511.
10. Coakley FV, Hricak H, Wefer AE, et al. Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology. 2001; 219:817-821. (Pubitemid 32476279)
11. Rouviere O, Valette O, Grivolat S, et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor-correlation with biopsy findings. Urology. 2004;63:922-927.
12. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int JRadiat Oncol Biol Phys. 2008;70:425-430.
13. Coakley FV, Teh HS, Qayyum A, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology. 2004;233:441-448.
14. Menard C, Smith IC, Somorjai RL, et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys. 2001;50:317-323.
15. Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. JMagn Reson Imaging. 2009;29:391-397.
16. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449-458.
17. Huisman HJ, Engelbrecht MR, Barentsz JO. Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging. 2001;13:607-614.
18. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223-332.
19. Kovar DA, Lewis M, Karczmar GS. A new method for imaging perfusion and contrast extraction fraction: input functions derived from reference tissues. J Magn Reson Imaging. 1998;8:1126-1134.
20. Vos PC, Hambrock T, Barentsz JO, et al. Automated calibration for computerized analysis of prostate lesions using pharmacokinetic magnetic resonance images. In: Yang GZ, Hawkes DJ, Rueckert D, et al, eds. Medical Image Computing and Computer-Assisted Intervention-MICCAI 2009. Part II, Volume 5761. Berlin, Germany: SpringerLink; 2009:836-843.
21. Huisman HJ, Karssemeijer N. Processing and displaying dynamic contrast-enhanced magnetic resonance imaging information 2008. Available at: http:// appft1.uspto.gov/netacgi/nph-Parser?Sect1 =PTO1&Sect2 = HITOFF&d= PG01&p=1&u = %2Fnetahtml%2FPTO%2Fsrchnum.html&r= 1&f=G&l= 50&s1 =%2220080125643%22.PGNR.&OS = DN/20080125643&RS=DN/ 20080125643.
22. Hambrock T, Futterer JJ, Huisman HJ, et al. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol. 2008;43:686-694.
23. Kaplan I, Oldenburg NE, Meskell P, et al. Real time MRI-ultrasound image guided stereotactic prostate biopsy. Magn Reson Imaging. 2002;20:295-299.
24. Singh AK, Kruecker J, Xu S, et al. Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJUInt. 2008;101:841-845.
25. Lowry M, Zelhof B, Liney GP, et al. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue. Invest Radiol. 2009;44:577-584.
26. Kim CK, Park BK, Park W, et al. Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging. In press.
27. Stephenson AJ, Scardino PT, Bianco FJ, et al. Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy. Curr Treat Options Oncol. 2004;5:357-365.
28. Gibbs P, Liney GP, Pickles MD, et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol. 2009;44:572-576.